The multiplex molecular diagnostics market has anticipated a CAGR of 5.4% during the forecast period, up from USD 23.2 Billion in 2022 to reach the valuation of USD 39.25 Billion by 2032.
| Attributes | Details |
|---|---|
| Multiplex Molecular Diagnostic (CAGR) | 5.4% |
| Multiplex Molecular Diagnostic (2022) | USD 23.2 Billion |
| Multiplex Molecular Diagnostic (2032) | USD 39.25 Billion |
The demand for multiplex molecular diagnostics is anticipated to increase at a decent rate in the forecast period. An increase in economic stability leads to improve funding in healthcare and research, which leads to an increase in sales of multiplex molecular diagnostics.
An increase in the incidence of gastrointestinal, respiratory and CNS infections has led to the growth of the multiplex molecular diagnostics market. That’s why there is a huge demand for multiplex molecular diagnostics.
As the clinical symptoms of these diseases are not pathogen-specific, therefore its differential diagnosis is broad. Previously, for performing microbiologic diagnosis, one needed a combination of antigen tests, microscopy, culture, and pathogen-specific PCR assays.
Due to this, there is a widespread use of and demand for multiplex molecular diagnostics in healthcare centres.
As the multiplex molecular diagnostic approach came into practice, it simplified testing algorithms and laboratory workflow, which led to an increase in sales of multiplex molecular diagnostics.
Multiplex molecular diagnostics have significantly increased the diagnostic yield with the launch of multiplex PCRs; the tests have become more sensitive than the routine culture or antigen detection. This leads to generating sales of multiplex molecular diagnostics in the multiplex molecular diagnostics market.
Still, there are a few limitations to the current multiplex molecular diagnostics test. In its current form, multiplex molecular diagnostics cannot detect all potential pathogens, which can decline the sales of multiplex molecular diagnostics.
Besides, a negative panel result doesn’t on entirely exclude infection. Further, with panel-based methodology, current platforms offer few or limited options to select which organism targets needs to be tested. Due to this, the demand for multiplex molecular diagnostics can decrease in the marketplace.
Explore FMI!
Book a free demo
Several industries are the key contributors to the multiplex molecular diagnostic market. Some of them are clinical research, laboratory, hospitals, academic & research centres and others.
The multiplex molecular diagnostic is used to detect infections such as tuberculosis, chlamydia, H1N1 virus and other diseases. Due to identifying such diseases, there is likely to increase in demand for multiplex molecular diagnostics by the end users.
These industries are likely to grow the multiplex molecular diagnosis market share along with sales of multiplex molecular diagnostics in the coming forecast period.
North America is anticipated to be the dominant revenue-generating region for the immunoaffinity columns multiplex molecular diagnostics market over the forecasting period. Demand for multiplex molecular diagnostics is likely to grow higher in this region as compared to others.
Many factors like well-developed high-tech diagnostic labs, the presence of a large number of key players, and favourable research funding are contributing to the high revenue generation in this region for multiplex molecular diagnostics market share.
After North America, Europe is anticipated to be the second most important region for the multiplex molecular diagnostics market share. This is attributed to the increased number of patient care and epidemiologic studies being conducted in this region.
The Asia Pacific regional multiplex molecular diagnostics market share is expected to grow at the fastest rate due to factors such as the rising adoption of advanced diagnostic technologies and the high prevalence of infectious diseases. This leads to an increase in sales of multiplex molecular diagnostics in the region.
The Middle East and Africa are expected to be the least lucrative region in the immunoaffinity columns multiplex molecular diagnostics market due to the lack of awareness about modern diagnostic techniques and the lack of advanced clinical laboratories.
Hence, there is expected to decline in the sales of multiplex molecular diagnostics in these regions.
Demand for multiplex molecular diagnostics is likely to increase in the manufacturing industries, which are playing a key role in the growth of the multiple molecular diagnostics market.
Some of the key players present in the multiplex molecular diagnostics market share include BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more. In addition, the presence of small and local manufacturers across the countries will account for competitiveness in the multiplex molecular diagnostics market.
These manufacturing companies are leading as key a player, which leads to an increase in the sales of multiplex molecular diagnostics in the forecast period.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.4% from 2022 to 2032 |
| Base year for estimation | 2022 |
| Historical data | 2015 to 2021 |
| Forecast period | 2023 to 2032 |
| Quantitative units | Revenue in USD billion and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | By Product, By Method, By End User & By Region |
| Regional scope | North America; Latin America; Europe; Middle East and; Africa (MEA); East Asia; South Asia; Oceania |
| Country scope | USA, Canada, Mexico, Brazil, Argentina, Germany, Italy, France, UK, Spain, Russia, India, Indonesia, Thailand, China, Japan, South Korea, Australia & New Zealand, GCC Countries, South Africa, North Africa |
| Key companies profiled | BD, bioMérieux SA, GenMark Diagnostics, Inc, Hologic, Luminex Corporation and many more |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The growth outlook for the multiplex molecular diagnostic market is predicted up to a CAGR of 5.4% during 2022 to 2032.
The North America region is expected to lead the multiplex molecular diagnostic market during forecast period.
The multiplex molecular diagnostic market is likely to hold the valuation of USD 39.25 Billion by 2032.
Healthcare Industry is expected to be a key driver in the multiplex molecular diagnostic market.
Glaucoma Treatment Market Overview – Trends & Forecast 2025 to 2035
Gastrointestinal Stent Market Growth – Trends & Forecast 2025 to 2035
Gel Implants Market Analysis - Trends, Share & Forecast 2025 to 2035
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Growth & Forecast 2025 to 2035
3D Printing Dental Devices Market Growth - Trends & Forecast 2025 to 2035
3D Printed Hip and Knee Implants Market Growth - Trends & Forecast 2025 to 2035
Multiplex Molecular Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
